Eliano Pio Navarese
Latest contributions
Left main bifurcation stenting
19 May 2022 – From EuroPCR 2022
Let's study, LIVE from Massy, France, the case of a 76-year-old man, hypertensive, dyslipidemic, who presented apical necrosis without ischemia in 2017, asymptomatic, referred for myocardial scintigraphy, and find out more about performing LM PCI, using imaging to guide the procedure.
EuroPCR 2022 Hotlines / Late-Breaking Trials in coronary artery disease: MASTER DAPT, CRUZ-HBR, DISCO RADIAL, and more!
17 May 2022 – From EuroPCR 2022
Find out more about various studies & registries in coronary artery disease! Abbreviated DAPT after complex PCI in high bleeding risk patients, comparing conventional and haemostatic dressings in radial access, angio-based QFR virtual PCI vs. conventional angio-guided PCI, CRUZ-HBR, CT-guided invasive coronary angiography in patients with...
Meta-analysis of elective coronary revascularization versus medical therapy alone - EuroPCR 2021 interview
27 May 2021 – From EuroPCR 2021
Luis Ortega Paz interviews Eliano Navarese, lead investigator of this meta-analysis of elective coronary revascularization versus medical therapy alone, released as a late-breaking trial at EuroPCR 2021:
- The gap in evidence that motivated this systematic review and meta-analysis
- The methodology employed
- The main findings
- How will these results impact clinical...
EuroPCR 2021 Hotlines / Late-Breaking Trials: PLA-pCi-EBO-pilot, CALM, ISCHEMIA, and more!
26 May 2021 – From EuroPCR 2021
Find out more about various studies & registries in stable CAD:
- Effects of visualization of PCI results on symptoms in chronic coronary syndrome
- Effect of Atorvastatin Therapy on Serial Changes of Coronary Flow And Plaque
- Initial results of a feasibility study of endovascular baroreflex amplification in heart failure patients
- Impact...
Meta-analysis of elective coronary revascularization vs medical therapy alone
18 May 2021 – From EuroPCR 2021
This session, originally broadcast during EuroPCR 2021, presents a meta-analysis based on 25 trials dealing with revascularization in patients with chronic coronary syndromes and enables our experts to discuss the strengths and weaknesses of this study.
